4//SEC Filing
Babu Yarlagadda S 4
Accession 0001127602-21-030610
CIK 0000882796other
Filed
Dec 8, 7:00 PM ET
Accepted
Dec 9, 4:38 PM ET
Size
8.2 KB
Accession
0001127602-21-030610
Insider Transaction Report
Form 4
Babu Yarlagadda S
VP Drug Discovery
Transactions
- Exercise/Conversion
Common Stock
2021-12-07$4.73/sh+62,000$293,260→ 245,156 total - Sale
Common Stock
2021-12-07$12.20/sh−30,100$367,220→ 215,056 total - Exercise/Conversion
Emp. Stock Option (Right to Buy)
2021-12-07−62,000→ 0 totalExercise: $4.73From: 2013-03-01Exp: 2022-03-01→ Common Stock (62,000 underlying)
Footnotes (1)
- [F1]The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $12.18 to $12.22. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
Documents
Issuer
BIOCRYST PHARMACEUTICALS INC
CIK 0000882796
Entity typeother
Related Parties
1- filerCIK 0001452635
Filing Metadata
- Form type
- 4
- Filed
- Dec 8, 7:00 PM ET
- Accepted
- Dec 9, 4:38 PM ET
- Size
- 8.2 KB